Hui-Hui Liu1, Ye-Xuan Cao1, Jing-Lu Jin1, Yuan-Lin Guo1, Cheng-Gang Zhu1, Na-Qiong Wu1, Ying Gao1, Rui-Xia Xu1, Qian Dong1, Ming-Hua Zheng2, Jian-Jun Li3. 1. State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167 BeiLiShi Road, XiCheng District, Beijing, 100037, People's Republic of China. 2. Department of Hepatology, MAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China. 3. State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167 BeiLiShi Road, XiCheng District, Beijing, 100037, People's Republic of China. lijianjun938@126.com.
Abstract
BACKGROUND AND AIMS: A consensus of experts suggests that nonalcoholic fatty liver disease (NAFLD) does not appropriately reflect current knowledge and metabolic-associated fatty liver disease (MAFLD) is supposed to be a more suitable overarching concept. However, the association of MAFLD with cardiovascular outcomes in patients with coronary artery disease has not been examined yet. Thus, this study aimed to assess the impact of MAFLD on major adverse cardiac events (MACEs) in patients with chronic coronary syndrome (CCS). METHODS: This study included 3306 patients with CCS who were diagnosed with MAFLD. Controls without MAFLD were matched (1:1) to cases by age and gender. All participants were followed up for the occurrence of MACEs. Finally, the association between MAFLD and the risk of MACEs was assessed. RESULTS: During an average of 55.09 ± 19.92 months follow-up, 376 and 248 MACEs were observed in MAFLD and control groups, respectively. When compared with controls, Kaplan-Meier analysis showed that patients with MAFLD had significantly lower event-free survival rate and multivariate Cox regression analysis further revealed that MAFLD group had significantly increased MACEs risk (both p < 0.05). Stratification analysis suggested that patients with MAFLD overlapped with NAFLD or MAFLD-only had 1.33-fold and 2.32-fold higher risk of MACEs respectively compared with controls (both p < 0.05). CONCLUSION: This study firstly showed that MAFLD was significantly associated with the risk of MACEs in patients with CCS. Moreover, this relationship remained unchanged irrespective of whether satisfying the NAFLD criteria, providing novel evidence for the good utility of MAFLD criteria in clinical practice.
BACKGROUND AND AIMS: A consensus of experts suggests that nonalcoholic fatty liver disease (NAFLD) does not appropriately reflect current knowledge and metabolic-associated fatty liver disease (MAFLD) is supposed to be a more suitable overarching concept. However, the association of MAFLD with cardiovascular outcomes in patients with coronary artery disease has not been examined yet. Thus, this study aimed to assess the impact of MAFLD on major adverse cardiac events (MACEs) in patients with chronic coronary syndrome (CCS). METHODS: This study included 3306 patients with CCS who were diagnosed with MAFLD. Controls without MAFLD were matched (1:1) to cases by age and gender. All participants were followed up for the occurrence of MACEs. Finally, the association between MAFLD and the risk of MACEs was assessed. RESULTS: During an average of 55.09 ± 19.92 months follow-up, 376 and 248 MACEs were observed in MAFLD and control groups, respectively. When compared with controls, Kaplan-Meier analysis showed that patients with MAFLD had significantly lower event-free survival rate and multivariate Cox regression analysis further revealed that MAFLD group had significantly increased MACEs risk (both p < 0.05). Stratification analysis suggested that patients with MAFLD overlapped with NAFLD or MAFLD-only had 1.33-fold and 2.32-fold higher risk of MACEs respectively compared with controls (both p < 0.05). CONCLUSION: This study firstly showed that MAFLD was significantly associated with the risk of MACEs in patients with CCS. Moreover, this relationship remained unchanged irrespective of whether satisfying the NAFLD criteria, providing novel evidence for the good utility of MAFLD criteria in clinical practice.
Authors: Zobair M Younossi; Yusuf Yilmaz; Ming-Lung Yu; Vincent Wai-Sun Wong; Marlen Castellanos Fernandez; Vasily A Isakov; Ajay K Duseja; Nahum Mendez-Sanchez; Yuichiro Eguchi; Elisabetta Bugianesi; Patrizia Burra; Jacob George; Jian-Gao Fan; George V Papatheodoridis; Wah Kheong Chan; Khalid Alswat; Hamid S Saeed; Ashwani K Singal; Manuel Romero-Gomez; Stuart C Gordon; Stuart K Roberts; Mohamed El Kassas; Marcelo Kugelmas; Janus P Ong; Saleh Alqahtani; Mariam Ziayee; Brian Lam; Issah Younossi; Andrei Racila; Linda Henry; Maria Stepanova Journal: Clin Gastroenterol Hepatol Date: 2021-11-09 Impact factor: 13.576
Authors: Ho Soo Chun; Mi Na Kim; Jae Seung Lee; Hye Won Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Seung Up Kim Journal: J Cachexia Sarcopenia Muscle Date: 2021-08-01 Impact factor: 12.910